The Biotech Growth Trust PLC (BIOG) is an LSE-listed investment company seeking to provide investors with a unique opportunity to gain exposure to one of the most dynamic and rapidly evolving sectors of the global economy through a diversified portfolio of shares and related securities of world-class biotechnology companies.

BIOG specialises in investing in a portfolio of growth-stage biotech businesses at the cutting edge of medical innovation that are sector leaders with first-mover advantages in key treatments for the future.

The portfolio is managed by OrbiMed, a leading global healthcare investment firm with deep expertise in biotechnology. It offers investors access to pioneering companies addressing tomorrow’s medical challenges – advancing solutions in areas like central nervous system disorders, oncology, cardiovascular disease, and gene and cell therapies. All of them strive to address unmet medical needs and enhance human lives.

How the team Invests

Portfolio Manager, Geoffrey Hsu provides an introduction to The Biotech Growth Trust

View our latest Annual Report

Find out more about our latest Annual Report

The Biotech Growth Trust AGM - Portfolio Manager Presentation

On Thursday 16 July 2026, The Biotech Growth Trust held its Annual General Meeting, where the Portfolio Manager, Geoff Hsu, provided investors with an update on BIOG's recent performance and how the portfolio is positioned to try and take advantage of the current long-term opportunities across the global biotech sector.

More insights

Investor hub

Factsheets

Documents

Research


To read the latest research notes that provide a timely insight into BIOG, please click on the following link.

How to invest


The Company’s shares are traded openly on the London Stock Exchange and can be purchased through a stockbroker, investment platform or other financial intermediary.

Latest insights

See the latest insights from The Biotech Growth Trust PLC.

12 Oct 2026

Kepler BIOG Portfolio Update – August 2026

01 Jul 2026

AGM Portfolio Manager Presentation – July 2026

01 May 2026

The Biotech Growth Trust (BIOG) – Podcast Interview, May 2026

The Biotech Growth Trust PLC at a glance

£322.7m

Our Net Asset Value

+30.7%

Five-year share price (total return)

[2.4p]

Dividends per share

Source: Frostrow Capital LLP

as at 31 July 2026

Register for RNS email alerts or to join email list

Please register if you would like to subscribe to receive updates on factsheets, announcements, news and information from The Biotech Growth Trust PLC.

How to invest

The Company’s shares are traded openly on the London Stock Exchange and can be purchased through a stockbroker, investment platform or other financial intermediary.